These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34367893)

  • 1. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
    Zhou J; Xu W; Liu Z; Wang C; Xia S; Lan Q; Cai Y; Su S; Pu J; Xing L; Xie Y; Lu L; Jiang S; Wang Q
    Acta Pharm Sin B; 2022 Apr; 12(4):1652-1661. PubMed ID: 34367893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
    Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
    Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
    Lan Q; Wang L; Jiao F; Lu L; Xia S; Jiang S
    J Med Virol; 2023 Jan; 95(1):e28143. PubMed ID: 36098460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.
    Trigueiro-Louro J; Correia V; Figueiredo-Nunes I; Gíria M; Rebelo-de-Andrade H
    Comput Struct Biotechnol J; 2020; 18():2117-2131. PubMed ID: 32913581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses.
    Cai Y; Xu W; Tang J; Cao N; Lan Q; Lu L; Jiang S
    Cell Biosci; 2021 Jul; 11(1):128. PubMed ID: 34238357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
    Lan Q; Chan JF; Xu W; Wang L; Jiao F; Zhang G; Pu J; Zhou J; Xia S; Lu L; Yuen KY; Jiang S; Wang Q
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.
    Xue S; Wang X; Wang L; Xu W; Xia S; Sun L; Wang S; Shen N; Yang Z; Huang B; Li S; Cao C; Calcul L; Sun X; Lu L; Cai J; Jiang S
    Cell Discov; 2022 Sep; 8(1):88. PubMed ID: 36075899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.
    Lan Q; Wang C; Zhou J; Wang L; Jiao F; Zhang Y; Cai Y; Lu L; Xia S; Jiang S
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.
    Duan Q; Xia S; Jiao F; Wang Q; Wang R; Lu L; Jiang S; Xu W
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
    Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
    Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Hu Y; Zhu Y; Yu Y; Liu N; Ju X; Ding Q; He Y
    Antiviral Res; 2023 Apr; 212():105571. PubMed ID: 36868315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.
    Xia S; Yan L; Xu W; Agrawal AS; Algaissi A; Tseng CK; Wang Q; Du L; Tan W; Wilson IA; Jiang S; Yang B; Lu L
    Sci Adv; 2019 Apr; 5(4):eaav4580. PubMed ID: 30989115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview on the seven pathogenic human coronaviruses.
    Kesheh MM; Hosseini P; Soltani S; Zandi M
    Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The New Generation
    Calistri A; Luganini A; Mognetti B; Elder E; Sibille G; Conciatori V; Del Vecchio C; Sainas S; Boschi D; Montserrat N; Mirazimi A; Lolli ML; Gribaudo G; Parolin C
    Microorganisms; 2021 Aug; 9(8):. PubMed ID: 34442810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
    Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
    Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
    Yu D; Zhu Y; Jiao T; Wu T; Xiao X; Qin B; Chong H; Lei X; Ren L; Cui S; Wang J; He Y
    Emerg Microbes Infect; 2021 Dec; 10(1):1227-1240. PubMed ID: 34057039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
    Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
    Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.